United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Here's why The Lancet's editor-in-chief thinks an mRNA vaccine to prevent COVID-19 could be groundbreaking.

What Investors Need To Know About Pfizer's Potential Coronavirus Vaccine

The Pfizer-BioNTech coronavirus vaccine could protect patients from the virus for a year, BioNTech CEO Ugur Sahin told "Mornings with Maria" on Thursday.

Pfizer coronavirus vaccine expected to protect patients for a year: BioNTech founder

Hold your fire until you understand the full story.

Pfizer CEO Sold Shares on Same Day as the Company's Coronavirus Vaccine News: Should You Be Outraged?

ETFs with exposure to Pfizer (PFE) are beginning to look good after the results of BNT162b2's Phase 3 trial.

ETFs to Consider on Pfizer's Vaccine Announcement

Pfizer CEO Albert Bourla sold nearly $5.6 million of the company's stock on Monday as the share price soared as much as 15% on the news that its COVID-19 vaccine candidate is 90% effective.

Pfizer CEO Sells Stock Same Day as Vaccine Announcement

Pfizer Inc. (NYSE: PFE) shares rose to a 52-week high of $41.99 Monday thanks to strong late-stage interim readout for the mRNA vaccine candidate BNT162b2 the company is co-developing with its German partner BioNTech SE – ADR (NASDAQ: BNTX). Some insider stock sales at the company are coinciding with the strong upward move.

Pfizer CEO Bourla Offloads $5.6M In Stock In Preplanned Sale Amid Vaccine Rally

Bourla is not the first pharmaceutical or biotech executive to cash in on his company's stock gains during the pandemic.

Pfizer CEO sold $5.6 million of stock as company announced vaccine data that sent shares soaring

Pfizer and BioNTech reached a supply deal Wednesday with the European Union for up to 300 million doses of their coronavirus vaccine. The EU will initially buy 200 million doses.

Pfizer, BioNTech Ink EU Deal For 300 Million Coronavirus Vaccine Doses

Pfizer CEO Albert Bourla filed to sell millions of dollars of his company's stock Monday -- the day the pharmaceutical giant announced positive data about its coronnavirus vaccine.

Pfizer's CEO sold $5.6 million in stock the day he announced promising vaccine news

The European Union has struck a deal to initially pay less for Pfizer's COVID-19 vaccine candidate than the United States, an EU official told Reuters as the bloc announced on Wednesday it had secured an agreement for up to 300 million doses.

Exclusive: Europe to pay less than U.S. for Pfizer vaccine under initial deal: source

Pfizer Inc Chief Executive Officer Albert Bourla has sold stake worth $5.56 million, according to a regulatory filing that showed the sale was made on Monday, the same day the drugmaker reported positive data on its experimental COVID-19 vaccine.

CEO sells stock worth $5.6 million on same day as Pfizer's COVID-19 vaccine update

After reporting stellar efficacy results for their vaccine candidate earlier this week, Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) announced a supply deal with the European Commission. What Happened: The U.S. pharma giant and its German partner said have reached an agreement with the European Commission to supply 200 million doses of their investigational mRNA vaccine, codenamed BNT162b2, against SARS-CoV-2.

Pfizer-BioNTech Seals 200M Dose Vaccine Supply Deal With European Commission

AstraZeneca

Gilead Sciences

Eli Lilly

Moderna

Stocks of Eli Lilly and Company (LLY), Pfizer, Inc. (PFE) and Moderna, Inc. (MRNA) have been in focus since the coronavirus outbreak as they have been the frontrunners in the vaccine race.

Vaccine Hopes Rise as Pharma Giants Inch Closer Toward Success

Pfizer CEO Albert Bourla cashed in on his company's coronavirus vaccine breakthrough. The executive sold more than $5.5 million worth of Pfizer stock on Monday — the same day the drugmaker said its experimental COVID-19 shot was more than 90 percent effective, records show.

Pfizer CEO Albert Bourla sold millions in stock on same day of vaccine reveal

Albert Bourla sold 132,508 Pfizer shares at a price of $41.94 apiece through a scheduled Rule 10b5-1 trading plan adopted on Aug. 19, one day after the company announced positive results from a Phase 1 study.

Pfizer CEO unloads $5.6M of stock as coronavirus vaccine hopes send shares soaring

An effective coronavirus vaccine candidate is just the tip of this gigantic pharmaceutical iceberg.

After Promising Coronavirus Vaccine Data, Is Pfizer a Buy?

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today positive top-line results from the Phase 3 JADE REGIMEN study. This 52-week study investigated abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200mg. Patients were randomized into one of three arms: 200mg, 100mg, or placebo. Both doses of abrocitini

Pfizer Announces Positive Results from Fifth Phase 3 Trial of Abrocitinib, Evaluating Safety and Efficacy Across Different Dosing Regimens

Pfizer Inc. and BioNTech SE announced Wednesday a deal to provide a supply of 200 million doses of its COVID-19 vaccine candidate to the European Union, marking the largest order for the potential vaccine to date. As part of the deal, the EU has an option to request an additional 100 million doses.

Pfizer, BioNTech reach deal to supply EU with 200 million doses of its COVID-19 vaccine candidate

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they have reached an agreement with the European Commission to supply 200 million doses of their investigational BNT162b2 mRNA-based vaccine candidate against SARS-CoV-2 to European Union (EU) Member States, with an option for the European Commission to request an additional 100 million doses. Deliveries are anticipated to start by the end of 2020, subject to clinical success and r

Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2

Inovio Pharmaceuticals

Johnson & Johnson

Investors are setting themselves up for disappointment.

5 Reasons Chasing COVID-19 Vaccine Stocks Is a Bad Idea

The probable winner of the vaccine race demonstrated that its candidate is at least 90% effective at preventing COVID-19 infection.

Pfizer's Coronavirus Vaccine Data Is Better Than Meets the Eye

Pfizer CEO Albert Bourla sold 62% of his stock on the same day the company announced its experimental COVID-19 vaccine succeeded in clinical trials. The announcement sent Pfizer's shares soaring almost 15% on the day.

Pfizer's CEO cashed out 60% of his stock on the same day the company unveiled the results of its COVID-19 vaccine trial

Standex

The Pfizer vaccine must be stored at -70 degrees Celsius. Anyone who wants to administer it will need an ultra low temp freezer. The market is mostly large companies like Thermo Fisher, but there is one public microcap, Standex International, that makes a limited line of these freezers.

Freeze! Standex International And The Pfizer Vaccine

“If they look at this data, and they say this data is solid, let's go ahead and approve it.”

News for Pfizer Stock (PFE)